Armstrong, MD • 919-668-8108 ClinicalTrials.gov Identifier: NCT00887640 Weekly Nanoparticle Albumin-Bound Paclitaxel Plus Weekly Cetuximab Plus Radiation Therapy in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma Principal
Search Results
Joyce Liu and Ursula Matulonis
. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996 ; 334 : 1 – 6 . 3. Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared
advanced melanoma Contact: Roswell Park Cancer Institute • 877-275-7724 • AskRPCI@roswellpark.org ClinicalTrials.gov Identifier: NCT01533948 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies
scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage
scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA
scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) Plus Weekly Cetuximab Plus Radiation Therapy
Deborah K. Armstrong
Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable
Alison K. Conlin and Andrew D. Seidman
anthracycline-containing chemotherapy. 304 Study Group . J Clin Oncol 1999 ; 17 : 1413 – 1424 . 6. Bishop JF Dewar J Toner GC . Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated
Urmeel Patel, Nicole Hook, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin, and Angel Rodriguez
patient underwent neoadjuvant chemotherapy with dose dense AC (ddAC) followed by paclitaxel. Following one month, the patient underwent radical mastectomy, followed by adjuvant treatment and periodic radiological imaging, along with circulating tumor DNA
-agent tivozanib in patients with platinum-resistant ovarian cancer Contact: Nikki Neubauer, MD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu ClinicalTrials.gov Identifier: NCT01853644 Phase I Trial of Intraperitoneal Nab-Paclitaxel
